Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Z-Butylidenephthalide polymer wafer implant - Everfront Biotech

Next Previous
Drug Profile

Z-Butylidenephthalide polymer wafer implant - Everfront Biotech

Alternative Names: BP/polymer wafer; Cerebraca wafer; HK-001; z-BP/polymer wafer

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Everfront Biotech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase modulators; Immunomodulators; Nuclear receptor subfamily 4 group A member 1 modulators; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma
  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis(In volunteers) in Taiwan (PO, Implant)
  • 08 Jan 2021 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in Taiwan (PO) (NCT03651349)
  • 05 Oct 2020 Phase I/II trial is still ongoing for Glioma in Taiwan (NCT03234595)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top